Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CTX460

Gene editing · Gene editing: serine protease inhibitor A1 (alpha-1 antitrypsin) (SERPINA1) · developed by CRISPR Therapeutics

Phase 1/2 Most advanced trial
CRSP Developer
1 Registered trials

What is CTX460?

CTX460 is a lipid nanoparticle formulation of a synthetic nucleotide template polymerase (SyNTase) editor that edits the SERPINA1 gene in vivo. It is being studied in adults with emphysema associated with severe alpha-1 antitrypsin deficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene editing
Targets
serine protease inhibitor A1 (alpha-1 antitrypsin) (SERPINA1)
Mechanism
Gene editing: serine protease inhibitor A1 (alpha-1 antitrypsin) (SERPINA1)
Therapy area
Respiratory
Developer
CRISPR Therapeutics (CRSP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07850076 Phase 1/2 Alpha-1 Antitrypsin Deficiency (AATD) Recruiting CRSP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alpha-1 Antitrypsin Deficiency (AATD)

Other drugs acting on SERPINA1

More from CRISPR Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.

Follow CRSP, the company behind CTX460

See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRSP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.